Business Context and Reporting Period
Mohawk Group Holdings, Inc. filed a Current Report on Form 8-K dated July 30, 2020. The filing identifies the registrant as Mohawk Group Holdings, Inc., although the request metadata identifies the company as Aterian, Inc. The company’s common stock traded on Nasdaq under the symbol MWK.
Material Financing Transaction
- On July 30, 2020, the company entered into an Equity Distribution Agreement with Canaccord Genuity LLC.
- The agreement permits the company to offer and sell, from time to time, up to $30.0 million of common stock through an at-the-market offering.
- The company is not obligated to sell any shares and may suspend or terminate the offering. The offering also terminates upon the sale of all offered shares.
- Canaccord Genuity will receive a 3.0% commission on gross proceeds from shares sold through the agent, plus reimbursement of certain expenses.
- The shares are offered pursuant to the company’s effective Form S-3 registration statement and related prospectus supplement dated July 30, 2020.
Use of Proceeds and Other Terms
Net proceeds, if any, are intended for general corporate purposes, including working capital, operating expenses and capital expenditures. The company may also use proceeds for acquiring, investing in or licensing complementary products, technologies or businesses.
The agreement includes customary indemnification and contribution obligations in favor of the sales agent. The filing includes a legal opinion from Paul Hastings LLP regarding the validity of the shares.
Financial Metrics and Outlook
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, operating guidance or other period-specific financial metrics. It also does not provide management commentary on operating performance or a forecast.
Investor Verification Points
- Verify the registrant’s corporate name and whether the filing should be attributed to Mohawk Group Holdings, Inc. or Aterian, Inc.
- Confirm the number and dollar value of shares actually sold under the $30.0 million facility, as the filing authorizes sales but does not report completed transactions.
- Assess dilution, commission costs and the effect of any equity issuance on existing shareholders.
- Review the full Equity Distribution Agreement, Form S-3 and prospectus supplement for additional offering terms and risk factors.
- Determine how any proceeds were ultimately used and whether the financing affected the company’s liquidity or capital plans.